STING MARK Universal Fiducial Marker System

Recruiting now · Not applicable

Conditions studied: Cancer

In brief

Currently available fiducial marker and fiducial insertion strategies are rudimentary, imprecise, not compatible with multiple insertion catheters/needles and are overall unreliable. STING-MARK device is the first universal, fully detachable and non-premounted radiopaque fiducial device system. Allowing biopsy prior to insertion, STING-MARK is easily and reliably delivered through-the-needle to the tumor, in order to accurately pinpoint its location for image-guided therapies. This study aims at establishing proof of concept for STING-MARK, by demonstrating its usability, reproducibility, radio-opacity and retention in a variety of clinically-relevant ex vivo organ samples.

Key facts

Study ID

NCT05465161

Run by

Centre hospitalier de l'Université de Montréal (CHUM)

People needed

100

Starts

2022-02-28

Expected to finish

2027-11-01

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing surgical resection of solid organs
• Recipients of solid organ transplantation

You may not qualify if…

• None

Where it is running

• CHUM — Montreal, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.